316149-08-3

Upstream product

• 121-90-4 m-nitrobenzoic acid chloride 
• 1673-47-8 3-chlorobenzhydrazide 
• 618-46-2 m-Chlorobenzoyl chloride 
• 618-94-0 3-nitrobenzoic acid hydrazide 
• 535-80-8 3-chlorobenzoate 
• 618-95-1 methyl 3-nitrobenzoate 

Downstream Products

• 575474-58-7 3-amino-[2-(3-chlorophenyl)-1,3,4-oxadiazol-5-yl]benzene 
• 107559-05-7 3-amino-(2-phenyl-1,3,4-oxadiazol-5-yl)benzene 
• 575474-56-5 [2-(3-chlorophenyl)-1,3,4-oxadiazol-5-yl]-3-nitrobenzene 
• 1418206-15-1 N-(3-(5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl)phenyl)-2-(3,4-dimethoxyphenyl)acetamide 

Relevant academic research and scientific papers

Synthesis and in vitro urease inhibitory activity of benzohydrazide derivatives, in silico and kinetic studies

Benzohydrazide derivatives 1–43 were synthesized via “one-pot” reaction and structural characterization of these synthetic derivatives was carried out by different spectroscopic techniques such as 1H NMR and EI-MS. The synthetic molecules were evaluated for their in vitro urease inhibitory activity. All synthetic derivatives showed good inhibitory activities in the range of (IC50 = 0.87 ± 0.31–19.0 ± 0.25 μM) as compared to the standard thiourea (IC50 = 21.25 ± 0.15 μM), except seven compounds 17, 18, 23, 24, 29, 30, and 41 which were found to be inactive. The most active compound of the series was compound 36 (IC50 = 0.87 ± 0.31 μM) having two chloro groups at meta positions of ring A and methoxy group at para position of ring B. The structure–activity relationship (SAR) of the active compounds was established on the basis of different substituents and their positions in the molecules. Kinetic studies of the active compounds revealed that compounds can inhibit enzyme via competitive and noncompetitive modes. In silico study was also performed to understand the binding interactions of the molecules (ligand) with the active site of enzyme.

2,4-Pyrimidinediamine Compounds and Their Uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Design, synthesis and biological activity evaluation of 2,5-diphenyl-1,3,4-oxadiazole derivatives as novel inhibitors of fructose-1,6-bisphosphatase

Fructose-1,6-bisphosphatase (FBPase), an important gluconeogenic enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate. The effort to discover new FBPase inhibitors was carried out by high-throughput screening (HTS) of a library of 56,000 lead-like compounds, and a 2,5-diphenyl-1,3,4-oxadiazole (3a, IC50 = 15.45 μM) which bearing no phosphate group was identified as a potential FBPase inhibitor for the first time. Structure-activity-relationship (SAR) research of a series of analogues obtained by modifying the substituent groups and replacing the 1,3,4-oxadiazole with several other heterocycles disclosed the key structure and substituent groups related to the binding with FBPase.